1-2 of 2
Volker Kliem
Close
Sort by
Journal Articles

Response to Rituximab Induction Is a Predictive Biomarker in Post-Transplant Lymphoproliferative Disorder (PTLD) and Allows Successful Treatment Stratification in an International Phase II Trial Including 152 Patients

Ralf Ulrich Trappe, MD, Daan Dierickx, MDPhD, Heiner Zimmermann, MD MB BChir, Franck Morschhauser, MD, Peter Mollee, MBBS, FRCPA, FRACP, MMSc, Jan M Zaucha, MD PhD, Martin H. Dreyling, MD PhD, Ulrich Dührsen, MD, Petra Reinke, MD, Gregor Verhoef, MD PhD, Marion Subklewe, MD, Andreas Hüttmann, MD, Thomas Tousseyn, MDPhD, Gilles A. Salles, MD PhD, Volker Kliem, MD, Corrado Tarella, Eric W Van Den Neste, MD PhD, Ingeborg A Hauser, MD, Olivier Gheysens, MD, Iannis Anagnostopoulos, MD, Veronique Leblond, MD PhD, Hanno Riess, MD, Sylvain Choquet, MD
Journal: Blood
Blood (2015) 126 (23): 816.
https://doi.org/10.1182/blood.V126.23.816.816
Published: 2015
Journal Articles

Reduction of Immunosuppression and Subsequent Rituximab Monotherapy or CHOP-Based Chemotherapy +/− Rituximab as a Treatment for PTLD Does No Impair the Renal Graft Function: A Matched Pair Control Analysis in 55 Renal Transplant Recipients with PTLD and 1075 Renal Transplant Controls

Ulrike Appel, Carl Hinrichs, Petra Reinke, Nina Babel, Hans H Neumayer, Klemens Budde, Martin Dreyling, Ulrich Dührsen, Volker Kliem, Silke Schüttrumpf, Ingeborg A Hauser, Hans G Mergenthaler, Bernd Dörken, Ioannis Anagnostopoulos, Hanno Riess, Ralf Trappe, On behalf of the German Study Group on PTLD
Journal: Blood
Blood (2008) 112 (11): 3613.
https://doi.org/10.1182/blood.V112.11.3613.3613
Published: 2008